Antidepressant properties of anticonvulsant drugs for bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 23, Issue 2, 2003, Pages 182-192

  Ernst, Carrie L ^a,b   Goldberg, Joseph F ^c,d  

^a CAMBRIDGE HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Payne Whitney Psychiatric Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PLACEBO; TOPIRAMATE; VALPROATE SEMISODIUM;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MONOTHERAPY; MOOD DISORDER; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; TREATMENT OUTCOME;

ACETIC ACIDS; AFFECT; AMINES; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CLINICAL TRIALS; CYCLOHEXANECARBOXYLIC ACIDS; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LITHIUM; TRIAZINES; VALPROIC ACID;

EID: 0037379557     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200304000-00011     Document Type: Review

References (103)

1. Pope HG Jr, McElroy SL, Keck PE Jr, et al. Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991;48:62-8.
2. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania: the Depakote Mania Study Group. JAMA 1994;271:918-24.
3. Martin LS, Joffe RT, Bebchuk JM. Clinical efficacy of carbamazepine. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in mood disorders. New York: Marcel Dekker; 1994:111-30.
4. Post RM, Uhde TW, Putnam FW, et al. Kindling and carbamazepine in affective illness. J Nerv Ment Dis 1982;170:717-31.
5. Post RM, Weiss SR. Sensitization, kindling, and anticonvulsants in mania. J Clin Psychiatry 1989;50(Suppl):23-30.
6. Bowden CL. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998;19:194-9.
7. Van Putten T, May RP. "Akinetic depression" in schizophrenia. Arch Gen Psychiatry 1978;35:1101-7.
8. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97.
9. Calabrese JR, Shelton MD, Bowden CL, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001;62(Suppl 14):34-41.
10. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470-8.
11. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
12. Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986;255:3138-42.
13. Hlastala SA, Frank E, Mallinger AG, et al. Bipolar depression: an underestimated treatment challenge. Depress Anxiety 1997;5:73-83.
14. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000;61:804-8.
15. Wehr TA, Goodwin FK. Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 1979;36:555-9.
16. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995;152:1130-8.
17. Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psych 2002;63:791-5.
18. Hirschfeld RMA, Bowden CL, Perlis RH, et al. Practice guideline for the treatment of patients with bipolar disorder [revision]. Am J Psychiatry 2002;159:1-50.
19. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guidelines series: medication treatment of bipolar disorder 2000. Postgrad Med 2000;special issue: 1-104.
20. Mallinger AG, Frank E, Barwell MM, et al. Effectiveness of traditional antidepressants is suboptimal in the depressed phase of bipolar disorder. Bipolar Disord 1999;1:41.
21. Moller HJ, Bottlender R, Grunze H, et al. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord 2001;67:141-6.
22. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993;13:397-408.
23. Bottlender R, Rudolf D, Strauss A, et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001;63:79-83.
24. Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry 2001;62:249-55.
25. Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988;145:179-84.
26. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000;157:124-6.
27. MacQueen GM, Young LT, Marriott MJ, et al. Dr. MacQueen and colleagues reply. Am J Psychiatry 2001;158:326.
28. Goldberg J. Spontaneous depression versus biphasic cycling. Am J Psychiatry 2001;158:325-6.
29. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12.
30. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000;61(suppl 9):97-104.
31. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic follow up conditions. Psychopharmacol Bull 1996;32:47-54.
32. Baastrup PC. Practical clinical viewpoints regarding treatment with lithium. Acta Psychiatr Scand 1969;207:12-6.
33. Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-5.
34. Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998;18:455-60.
35. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108-11.
36. Swann AC, Bowden CL, Morris D, et al. Depression during mania: treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37-42.
37. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974;30:229-33.
38. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol. 1980;13:156-67.
39. Tohen M, Waternaux CM, Tsuang MT, et al. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord 1990;19:79-86.
40. Prien RF, Caffey EM Jr, Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness: report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973;28:337-41.
41. Bowden CL, Ghaemi SN, Gyulai L, et al. Lamotrigine delays mood episodes in recently depressed bipolar I patients (605 data). Presented at the 155th Annual Meeting of the American Psychiatric Association, May 18-23, 2002. Philadelphia: American Psychiatric Association, 2002.
42. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976;33:117-20.
43. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
44. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003 (in press).
45. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002;63:146-51.
46. Lambert PA, Carraz G, Borselli S, et al. Neuropsychotropic action of a new anti-epileptic agent: depamide. Ann Med Psychol (Paris) 1966;124:707-10.
47. Okuma T, Kishimoto A, Inoue K, et al. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: a preliminary report. Folia Psychiatr Neurol Jpn 1973;27:283-97.
48. Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983;140:1602-4.
49. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980;137:782-90.
50. Lambert PA, Venaud G. Comparative study of valpromide versus lithium in the treatment of bipolar disorder. Nervure 1992;5:57-65.
51. Sachs G, Altshuler L, Ketter T, et al. Divalproex versus placebo for the treatment of bipolar depression. Presented at the 40th Annual Meeting of the American College of Neuropsychopharmacology, December 9-13, 2001, Waikoloa, Hawaii.
52. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression: Lamictal 602 Study Group. J Clin Psychiatry 1999;60:79-88.
53. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-14.
54. Deleted in page proofs.
55. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002;4:207-13.
56. Lambert PA. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984:33-44.
57. Lambert PA, Venaud G. Utilisation de valpromide en therapeutique psychiatrique. L'Encephale 1987;8:367-73.
58. Calabrese JR, Markovitz PJ, Kimmel SE, et al. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992;12:53S-6S.
59. Brady KT, Sonne SC, Anton R, et al. Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. J Clin Psychiatry 1995;56:118-21.
60. Goldberg JF, Garno JL, Leon AC, et al. A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999;60:733-40.
61. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001;62:199-203.
62. Calabrese JR, Woyshville MJ, Kimmel SE, et al. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993;13:280-3.
63. Puzynski S, Klosiewicz L. Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders. Psychopharmacol Bull 1984;20:151-9.
64. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J Affect Disord 1984;6:115-21.
65. Puzynski S, Klosiewicz L. Valproic acid amide as a prophylactic agent in affective and schizoaffective disorders. In: Emrich HM, Okuma T, Muller AA, eds. Anticonvulstants in affective disorders. Amsterdam: Elsevier Science Publishers, 1984:68-75.
66. Winsberg ME, DeGolia SG, Strong CM, et al. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001;67:207-12.
67. Sharma V, Persad E, Mazmanian D, et al. Treatment of rapid cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993;38:137-9.
68. Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997;154:1456-8.
69. Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971;12:325-34.
70. Dalby MA. Behavioral effects of carbamazepine. Adv Neurol 1975;11:331-44.
71. Gerner RH, Stanton A. Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? J Clin Psychopharmacol 1992;12:57S-63S.
72. Okuma T, Inanaga K, Otsuki S, et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl) 1981;73:95-6.
73. Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry 1996;39:896-9.
74. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29-34.
75. Kishimoto A, Ogura C, Hazama H, et al. Long-term prophylactic effects of carbamazepine in affective disorder. Br J Psychiatry 1983;143:327-31.
76. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114-8.
77. Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986;47:490-4.
78. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988;153:198-204.
79. Kramlinger KG, Post RM. The addition of lithium to carbamazepine: antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry 1989;46:794-800.
80. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996;29:103-7.
81. US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 2001;57:S62-8.
82. Dimond KR, Pande AC, Lamoreaux L, et al. Effect of gabapentin (Neurontin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:407-17.
83. Harden CL, Lazar LM, Pick LH, et al. A beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999;40:1129-34.
84. Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2:249-55.
85. Altshuler LL, Keck PE Jr, McElroy SL, et al. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1999;1:61-5.
86. Young LT, Robb JC, Patelis-Siotis I, et al. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry 1997;42:851-3.
87. Young LT, Robb JC, Hasey GM, et al. Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999;55:73-7.
88. Ghaemi SN, Katzow JJ, Desai SP, et al. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 1998;59:426-9.
89. Ghaemi SN, Goodwin FK. Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J Affect Disord 2001;65:167-71.
90. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19:341-8.
91. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000;20:467-71.
92. Smith D, Baker G, Davies G, et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-22.
93. Suppes T, Brown ES, McElroy SL, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999;53:95-8.
94. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17:185-9.
95. Kusumakar V, Yatham LN. Lamotrigine treatment of rapid cycling bipolar disorder. Am J Psychiatry 1997;154:1171-2.
96. Fatemi SH, Rapport DJ, Calabrese JR, et al. Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997;58:522-7.
97. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999;156:1019-23.
98. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002;51:253-60.
99. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000;61:841-50.
100. Bowden CL, Calabrese JR, McElroy SL, et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999;45:953-8.
101. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000;47:1025-33.
102. Hussein MZ, Chaudry ZA, Hussain S. Topiramate in the treatment on refractory bipolar depression: A 3-year follow-up. Presented at the 4th International Conference on Bipolar Disorder, Pittsburgh, Pennsylvania, June 14-16, 2001.
103. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53:S53-67.